Estimate risk of developing cancer |
BRCA1 germline mutation (breast and ovarian cancer) |
Easton et al., 1995; Hall et al., 1990
|
Screening |
Prostate specific antigen (prostate cancer) |
Lin et al., 2008
|
Differential diagnosis |
Immunohistochemistry to determine tissue of origin |
|
Determine prognosis of disease |
21 gene recurrence score (breast cancer) |
Paik et al., 2004
|
Predict response to therapy |
KRAS mutation and anti‐EGFR antibody (colorectal cancer) |
Allegra et al., 2009
|
HER2 expression and anti‐Her2 therapy (breast and gastric cancer) |
Bang et al., 2010; Piccart‐Gebhart et al., 2005; Romond et al., 2005
|
Estrogen receptor expression (breast cancer) |
EBCTCG 2011
|
Monitor for disease recurrence |
CEA (colorectal cancer) |
Locker et al., 2006
|
AFP, LDH, βHCG (germ cell tumor) |
Gilligan et al., 2010
|
Monitor for response or progression in metastatic disease |
CA15‐3 and CEA (breast cancer) |
Harris et al., 2007
|